These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36824056)

  • 1. Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow.
    Bazinet A; Wang A; Li X; Jia F; Mo H; Wang W; Wang SA
    Cytometry B Clin Cytom; 2023 Feb; ():. PubMed ID: 36824056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia.
    Salama ME; Otteson GE; Camp JJ; Seheult JN; Jevremovic D; Holmes DR; Olteanu H; Shi M
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
    Nguyen PC; Nguyen V; Baldwin K; Kankanige Y; Blombery P; Came N; Westerman DA
    Br J Haematol; 2023 Aug; 202(4):760-770. PubMed ID: 37052611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Acute Leukemia by Multiparameter Flow Cytometry with the Assistance of Artificial Intelligence.
    Zhong P; Hong M; He H; Zhang J; Chen Y; Wang Z; Chen P; Ouyang J
    Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.
    Aruga Y; Ikeda C; Matsushita H; Makita S; Fukuhara S; Munakata W; Izutsu K; Matsui H
    Sci Rep; 2024 Jun; 14(1):13452. PubMed ID: 38862612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
    Goshaw JM; Gao Q; Wardrope J; Dogan A; Roshal M
    Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
    Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
    Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.
    Gao Q; Roshal M
    Curr Protoc; 2022 Aug; 2(8):e503. PubMed ID: 35980134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.
    Farren TW; Sadanand KS; Agrawal SG
    Front Oncol; 2020; 10():597730. PubMed ID: 33344247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics.
    Riva G; Luppi M; Tagliafico E
    Br J Haematol; 2023 Aug; 202(4):715-717. PubMed ID: 37092558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 14. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
    Front Oncol; 2019; 9():689. PubMed ID: 31555576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
    Brett VE; Dilhuydy MS; Lechevalier N; Adjibabi AN; Gros FX; Forcade É; Letestu R; Vial JP
    Ann Biol Clin (Paris); 2023 Oct; 81(4):379-387. PubMed ID: 37864443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
    Momen N; Tario J; Fu K; Qian YW
    J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
    Bazinet A; Rys RN; Barry A; Greenwood CMT; Young YK; Mendoza A; LaPorta I; Wever CM; Mercier FE; Johnson NA
    Leuk Lymphoma; 2021 Oct; 62(10):2352-2359. PubMed ID: 34020575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
    D'Arena G; Sgambato A; Volpe S; Coppola G; Amodeo R; Tirino V; D'Auria F; Statuto T; Valvano L; Pietrantuono G; Deaglio S; Efremov D; Laurenti L; Aiello A
    Hematol Oncol; 2022 Dec; 40(5):835-842. PubMed ID: 35667043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.
    Bento L; Correia R; de Sousa F; Vaz A; Pedro E; Schimidell D; Millan N; Passaro M; Barroso R; Bacal N
    Cytometry B Clin Cytom; 2020 Nov; 98(6):529-535. PubMed ID: 32251553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.